China News Service, May 6, According to foreign media reports, on May 4 local time, the European Medicines Agency announced that it had begun to review the new crown vaccine ("Kexing Vaccine") of China Kexing Biological Products Co., Ltd. (referred to as "Kexing Vaccine"). To evaluate its effectiveness and safety.
Data Map: Kexing Vaccine.
Photo by China News Agency reporter Hou Yu
According to reports, the European Medicines Agency stated that its decision to start the review was based on preliminary results of laboratory and clinical studies.
The agency said in a statement, "These studies show that this vaccine can stimulate the production of antibodies," and said Kexing vaccine "may help prevent this disease (new coronary pneumonia)."
According to the report, the agency also stated that its experts will evaluate the data later "to determine whether the benefits of the vaccine outweigh the risks."
At the same time, it also stated that the rolling review will continue until "there is sufficient evidence to support its formal application for marketing authorization," adding that the relevant timetable cannot be predicted.
According to reports, the European Medicines Agency has currently approved 4 new coronavirus vaccines and is reviewing the other 3 vaccines.
However, Kexing Company has not yet submitted any application for seeking market authorization in the EU.
So far, Coxing vaccine has been launched in many countries including Brazil, Chile and Turkey.
In addition, many heads of government, including Turkish President Erdogan, Indonesian President Joko, and Chilean President Pinera, have also been vaccinated against Kohin.
After the widespread inoculation of Kexing vaccine, many parties have given positive comments on the effect of the vaccine.
Chile’s Minister of Science and Technology Cove has previously stated that the latest data on the protective effect of Coxing’s vaccine released by the Chilean Ministry of Health is “exciting”.
He said that research has shown that China Kexing Vaccine is "very effective" in preventing symptomatic infections, preventing hospitalization, avoiding severe illness and death due to infection.
In addition, Bloomberg in the United States recently cited the views of two Australian experts on the Coxing vaccine.
Among them, Fiona Russel, a professor at the Murdoch Children’s Research Institute in Australia, said that the Coxing vaccine is “extremely effective” in preventing severe new crown infections. The effectiveness of protection against new crown infections that require medical intervention is about 84%. The effectiveness of the protection against re-coronary symptoms is 100%.
Russel pointed out that this is exactly what the public expects for the new crown vaccine, that is, it can provide better protection against severe infections.